777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Regeneron Pharmaceuticals Reports $127 Million IPR&D Charge for Q2 2026
2026 Annual Meeting Results - Directors Elected at Regeneron Pharmaceuticals
Reports First Quarter 2026 Financial and Operating Results
Annual Report to Security Holders
Earnings Release
Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Investor Presentation
Reports Third Quarter 2025 Financial and Operating Results
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Quarterly Holdings Report for Institutional Managers
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence